Proteintech Partners With AI Driven BenchSci to Boost Researchers’ Antibody Data Searches

December 3, 2018


Proteintech, the benchmark in antibodies since 2001, and BenchSci, a life science machine learning startup backed by Google’s AI fund, have announced a new partnership to accelerate science by overcoming a key challenge that biomedical researchers face selecting antibodies.

When researchers use antibodies that lack specificity or yield inferior results in specific applications, it wastes time, money, and sometimes samples. This can delay research projects, the publication of research results, and ultimately the development of new therapies.

To prevent this, researchers review scientific papers for published data on antibodies when planning experiments. But more than 38 million scientific papers have been published since 1980, a number that doubles every nine years. It can take researchers hours, and sometimes days, to find useful data—if they can find it at all.

Proteintech’s partnership with BenchSci aims to solve this problem by combining the company’s catalog with BenchSci’s industry leading artificial intelligence platform. BenchSci will use machine learning to identify published data for Proteintech’s catalog in open- and closed-access datasets, display related published figures, and allow researchers to search by important experimental variables.

“BenchSci’s platform is rocket fuel for the advancement of science,” says Will Olds, Scientific Officer at Proteintech. “The ability to quickly comb over millions of pieces of data and find only the relevant data for a specific biological question allows scientists to make better decisions faster than ever before. We are excited to join forces with them to help accelerate scientific discovery.”

BenchSci decodes the world’s biological data to reduce the time, uncertainty, and cost of biomedical research. Researchers waste time and money on antibodies that don't work. This slows studies, destroys samples, and leaves patients waiting for treatments. Artificial intelligence can solve the problem, and BenchSci is building it. BenchSci’s technology helps researchers find reliable antibodies 24x faster and 75% cheaper. Backed by Google’s AI fund, BenchSci applies machine learning to decode comprehensive open- and closed-access datasets, display published figures with no commercial bias, and allow researchers to search by important experimental variables. BenchSci now powers discoveries in 15 of the top 20 pharmaceutical companies and 1,300 academic institutions. Academic researchers can sign up free at http://www.benchsci.com. Industry researchers can request a demo at http://www.benchsci.com/contact/.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.